Patents Assigned to SDG, Inc.
-
Publication number: 20230172868Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.Type: ApplicationFiled: February 1, 2023Publication date: June 8, 2023Applicant: SDG, Inc.Inventor: W. Blair Geho
-
Patent number: 11517529Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.Type: GrantFiled: January 30, 2020Date of Patent: December 6, 2022Assignee: SDG, Inc.Inventors: John R. Lau, W. Blair Geho
-
Patent number: 11077173Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.Type: GrantFiled: June 30, 2020Date of Patent: August 3, 2021Assignee: SDG, Inc.Inventor: W. Blair Geho
-
Patent number: 11071715Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.Type: GrantFiled: September 6, 2019Date of Patent: July 27, 2021Assignee: SDG, Inc.Inventor: W. Blair Geho
-
Patent number: 10918700Abstract: The invention provides methods of treating a subject having diabetes mellitus and/or a metabolic derangement.Type: GrantFiled: April 10, 2020Date of Patent: February 16, 2021Assignee: SDG, Inc.Inventor: W. Blair Geho
-
Publication number: 20200323961Abstract: The invention provides methods of treating a subject having diabetes mellitus and/or a metabolic derangement.Type: ApplicationFiled: April 10, 2020Publication date: October 15, 2020Applicant: SDG, Inc.Inventor: W. Blair Geho
-
Patent number: 10751418Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.Type: GrantFiled: March 5, 2013Date of Patent: August 25, 2020Assignee: SDG, Inc.Inventors: W. Blair Geho, John R. Lau
-
Patent number: 10568835Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.Type: GrantFiled: January 8, 2015Date of Patent: February 25, 2020Assignee: SDG, Inc.Inventors: John R. Lau, W. Blair Geho
-
Patent number: 10463616Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.Type: GrantFiled: May 14, 2018Date of Patent: November 5, 2019Assignee: SDG, Inc.Inventors: John R. Lau, W. Blair Geho
-
Patent number: 10004686Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.Type: GrantFiled: June 12, 2013Date of Patent: June 26, 2018Assignee: SDG, Inc.Inventors: John R. Lau, W. Blair Geho
-
Patent number: 9943602Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.Type: GrantFiled: May 2, 2014Date of Patent: April 17, 2018Assignee: SDG, Inc.Inventors: W. Blair Geho, John R. Lau
-
Patent number: 9145453Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.Type: GrantFiled: March 26, 2010Date of Patent: September 29, 2015Assignee: SDG, Inc.Inventors: W. Blair Geho, John R. Lau
-
Patent number: 9034372Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.Type: GrantFiled: October 10, 2014Date of Patent: May 19, 2015Assignee: SDG, Inc.Inventors: John R. Lau, W. Blair Geho
-
Patent number: 8962015Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.Type: GrantFiled: September 28, 2007Date of Patent: February 24, 2015Assignee: SDG, Inc.Inventors: John R. Lau, W. Blair Geho
-
Patent number: 8846053Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.Type: GrantFiled: June 15, 2010Date of Patent: September 30, 2014Assignee: SDG, Inc.Inventors: W. Blair Geho, John R. Lau
-
Publication number: 20140243430Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.Type: ApplicationFiled: May 2, 2014Publication date: August 28, 2014Applicant: SDG, INC.Inventors: W. BLAIR GEHO, JOHN R. LAU
-
Publication number: 20130183270Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.Type: ApplicationFiled: March 5, 2013Publication date: July 18, 2013Applicant: SDG, Inc.Inventor: SDG, Inc.
-
Patent number: 8303983Abstract: A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use.Type: GrantFiled: January 14, 2010Date of Patent: November 6, 2012Assignee: SDG, Inc.Inventors: John R. Lau, W. Blair Geho, George H. Snedeker
-
Patent number: 8257735Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.Type: GrantFiled: November 23, 2010Date of Patent: September 4, 2012Assignee: SDG, IncInventors: John R. Lau, W. Blair Geho
-
Publication number: 20110135725Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.Type: ApplicationFiled: May 16, 2006Publication date: June 9, 2011Applicant: SDG, Inc.Inventors: John R. Lau, W. Blair Geho